Rockwell Medical, Inc.

RMTI

$7.99

-1.05%

2026-09-03 16:00:00 EDT-$0.09

Salud

Fabricantes de medicamentos - Especialidad y genéricos

NASDAQ

Negociación activa

Rockwell Medical, Inc., junto con sus empresas asociadas, opera como una firma de biotecnología farmacéutica especializada en tratamientos para la enfermedad renal ...

Evolución del precio de RMTI

$7.99

-1.05%-$0.09

Máximo—

Mínimo—

Máx. 52s-56.7%

Vol. rel.—

Intervalo

Rango4.7h

Volumen—SMA5SMA10

—

Rockwell Medical, Inc. is a fully-integrated biopharmaceutical company focused on treatments for chronic and end-stage kidney disease. Established in 1996 and headquartered in Wixom, Michigan, the company specializes in both innovative iron replacement therapies and essential hemodialysis products. Its key product line, Triferic (including Triferic Dialysate and Triferic AVNU), is ...Rockwell Medical, Inc. is a fully-integrated biopharmaceutical company focused on treatments for chronic and end-stage kidney disease. Established in 1996 and headquartered in Wixom, Michigan, the company specializes in both innovative iron replacement therapies and essential hemodialysis products. Its key product line, Triferic (including Triferic Dialysate and Triferic AVNU), is an iron replacement therapy designed to maintain hemoglobin levels in dialysis patients without increasing iron stores. Beyond this, Rockwell Medical manufactures and distributes a comprehensive range of hemodialysis concentrates, including acid concentrates (CitraPure, Dri-Sate, RenalPure) and powder bicarbonate concentrates (RenalPure, SteriLyte), which are crucial for removing toxins and replacing essential nutrients in patients' blood. The company also supplies ancillary items such as blood tubing, fistula needles, dialyzers, dressings, and cleaning agents. Rockwell Medical primarily serves medium and small-sized dialysis chains and independent dialysis centers, aiming to become a leading global supplier of hemodialysis concentrates. The company is actively developing additional therapeutic candidates for acute heart failure and home infusion therapy. With a workforce of approximately 157 employees, Rockwell Medical has a strong focus on long-term growth and innovation, positioning itself as a key player in the dialysis market. Its operations span both domestic and international markets, supported by a dedicated team and a commitment to quality and life-sustaining solutions.ExpandirContraer

Fundación

1996

Empleados

157

CEO

Mark Strobeck

Nombre completo

Rockwell Medical, Inc.

Sector

Salud

Industria

Fabricantes de medicamentos - Especialidad y genéricos

ROE

-14.03%

Capitalización

$0.03B

Ratio corriente

3.25

WACC

11.22%

ROIC

-8.82%

Información de contacto

https://www.rockwellmed.com

248 960 9009

30142 South Wixom road, Wixom, MI 48393

Métricas clave de RMTI

Instantánea

Último / TTM · 6 periodos

Capitalización

$31.52M

ROCE

-10.0%

EV / EBITDA

-14.93x

-0.1% YoY

Rendimiento FCF

4.9%

+8.9% YoY

Ciclo de conversión de efectivo

41.4d

Ratio corriente

3.25

Resumen rápido

TTM —

Positive CCC

Aspectos financieros de RMTI

Tendencia de rentabilidad

Último / TTM · 6 periodos

Margen bruto

17.7%

Margen neto

-7.3%

PER

-5.74x

n/d

Deuda / capital

0.40

n/d

Ratio corriente

3.25

Rendimiento del dividendo

0.0%

Comprensión

TTM —

La cobertura de intereses es débil

Calendario de RMTI

Próximamente

30 sept 2026En 26 días
Q3 FY2026 · Resultados estimados
BPA est. $-0.18 · Ingresos $18.27M · 1 analistas
30 dic 2026
Q4 FY2026 · Resultados estimados
BPA est. $-0.10 · Ingresos $19.07M · 1 analistas
31 dic 2026
FY2026 · Resultados anuales estimados
BPA est. $-0.94 · Ingresos $72.49M · 1 analistas
30 mar 2027
Q1 FY2027 · Resultados estimados
BPA est. $-0.13 · Ingresos $18.85M · 1 analistas

Historial reciente

13 ago 2026
Q2 FY2026 · Resultados publicados
BPA $-0.34 · Ingresos $17.78M
Ver documento
7 may 2026
Q1 FY2026 · Resultados publicados
BPA $-0.41 · Ingresos $17.34M
Ver documento
26 mar 2026
FY2025 · Resultados anuales
BPA $-1.50 · Ingresos $69.26M
Ver documento
12 nov 2025
Q3 FY2025 · Resultados publicados
BPA $-0.50 · Ingresos $15.93M
Ver documento
14 ago 2025
Q2 FY2025 · Resultados publicados
BPA $-0.43 · Ingresos $16.07M
Ver documento
31 mar 2025
Q1 FY2025 · Resultados publicados
BPA $-0.44 · Ingresos $18.91M

Estados financieros de RMTI

Tendencia de 5 años (ingresos, beneficios, FCF)

Métrica	Último	InteranualYoY significa Year-over-Year (interanual). Compara el último valor anual con el valor anual anterior para mostrar la fortaleza de la tendencia a largo plazo.	TrimestralQoQ significa Quarter-over-Quarter (intertrimestral). Compara el último trimestre con el trimestre inmediatamente anterior para mostrar cambios de impulso a corto plazo.
IngresosEl dinero total que entró por la puerta principal al vender cosas, antes de pagar una sola factura. Piensa en esto como el gran total de cada compra con tarjeta de los clientes. (YoY compara el rendimiento de este año con el del año pasado, mientras que QoQ compara los tres meses actuales con los tres anteriores).	$69.3M	-31.8%	+2.6%
Beneficio netoEl resultado final absoluto. Si la empresa pagara a cada proveedor, empleado, banquero y recaudador de impuestos, este es el dinero real que queda en su bolsillo al final del día.	$-5.3M	-1007.1%	+27.0%
Margen brutoEl margen básico. Si venden unas zapatillas de 100 dólares, este porcentaje indica cuánto de ese precio es ganancia justo después de pagar el caucho y los cordones, pero antes de pagar el alquiler de la tienda o los anuncios de televisión.	+16.9%	-2.0%	+9.1%
Margen operativoLa puntuación de eficiencia del 'trabajo diario'. De cada dólar que gasta un cliente, esto muestra cuántos centavos mantiene la empresa después de fabricar el producto Y pagar todos los gastos generales corporativos (como salarios, marketing y mantener las luces encendidas).	-6.8%	-1230.6%	+30.1%
Margen netoEl porcentaje final que se lleva a casa. Cuando se eliminan todos los costos concebibles, impuestos y pagos de intereses, este es el número exacto de centavos que la empresa realmente se queda de cada dólar en ventas.	-7.7%	-1522.3%	+28.8%
Flujo de caja libreEl santo grial del efectivo corporativo. Es el dinero físico gastable que queda después de que el negocio paga sus operaciones diarias Y compra las actualizaciones grandes y costosas (como nuevas fábricas o servidores) que necesita para sobrevivir. Este es el dinero 'libre' que pueden usar para pagar dividendos o recomprar acciones.	$-1.2M	-137.6%	+347.1%
Margen FCFLa tasa definitiva de conversión de efectivo. Muestra qué tan buena es la empresa para convertir ventas regulares directamente en efectivo frío, duro y gastable. Un porcentaje alto significa que el negocio es una auténtica máquina de imprimir dinero.	-1.7%	-155.2%	+341.0%
Deuda/PatrimonioEl indicador de riesgo financiero. Compara cuánto del imperio de la empresa se construyó con dinero prestado (préstamos) frente al dinero propio de los propietarios (accionistas). Un número alto significa que están muy apalancados y juegan un juego más arriesgado; un número bajo significa que juegan a lo seguro.	33.7%	-18.8%	-1.0%
Ratio corrienteLa verificación de supervivencia de 12 meses. Simplemente compara el efectivo que tienen ahora mismo (más cosas que pueden convertirse rápidamente en efectivo) con las facturas inmediatas que absolutamente deben pagar este año. Una puntuación superior a 1 significa que tienen suficiente en la billetera para cubrir las próximas facturas sin entrar en pánico.	3.98x	+51.6%	-13.1%
Activos totalesEl tamaño absoluto del imperio de la empresa. Agrupa absolutamente todo lo valioso que poseen, desde el efectivo en la caja registradora y el inventario en el almacén, hasta las patentes de software en la bóveda y las fábricas en el suelo.	$57.1M	-3.5%	-1.6%

Real vs estimado

A Dec 31Q Jun 30

Métrica	Anual (real vs estimado)	Sorpresa anual	Trimestral (real vs estimado)	Sorpresa trimestral
EPS Surprise	-1.50 vs -1.15	-30.4%	-0.34 vs -0.23	-44.7%
Revenue Surprise	$69.3M vs $69.5M	-0.4%	$17.8M vs $17.8M	-0.2%

Transacciones de insiders de RMTI

Compras (A)

Since Jul 1, 2026

Ventas (D)

Since Jul 1, 2026

Acciones mensuales compradas/vendidas con tendencia del precio de cierre (fuente diaria compartida)

Resumen de trading de insiders

Fecha	Ejecutivo	Cargo	Valor	Lado	Acciones	Precio
Jul 1, 2026	Dawson Joseph H	director	Common Stock	A	9,633	—
Jul 1, 2026	Nissenson Allen	director	Common Stock	A	9,633	—
Jul 1, 2026	Lau Joan	director	Common Stock	A	9,633	—
Jul 1, 2026	Radie Robert S	director	Common Stock	A	9,633	—
Jul 1, 2026	COOPER JOHN G	director	Common Stock	A	9,633	—

Transcripción de la llamada de resultados de RMTI

1 segmentos de transcripción

Q2 2026

Ponente desconocido

Operator: Thank you. Good morning and welcome to Rockwell Medical's second quarter 2026 results conference call and webcast. Please note, this event is being recorded. At this time, I would like to turn the conference call over to Heather Hunter, Chief Operating Officer at Rockwell Medical. Heather, please go ahead. Heather Hunter: Good morning, everyone, and thank you for joining us for this update on Rockwell Medical. Joining me on today's conference call are Dr.Mark Strobeck, Rockwell Medical's President and CEO, and Jesse Neri, Rockwell Medical's CFO. Before we begin, I would like to remind you that this conference call will contain forward-looking statements about Rockwell Medical within the meaning of the federal securities laws, including but not limited to the types of statements identified as forward-looking in our annual report on Form 10-K and our subsequent periodic reports filed with the SEC. These statements are subject to risks and uncertainties that could cause actual results to differ. Please note that these forward-looking statements reflect our opinions and expectations only as of today. Except as this concept is required by law, we specifically disclaim any obligation to update or revise these forward-looking statements in light of new information or future events. Factors that could cause actual results or outcomes to differ materially from those expressed in, or implied by, such forward-looking statements are discussed in greater detail in our periodic reports filed with the SEC. Rockwell Medical's quarterly report on Form 10-Q for the 3 months ended June 30, 2026, was filed prior to this call and provides a full analysis of the company's business strategy, as well as the company's second quarter 2026 results. The reconciliation of non-GAAP measures we discuss on today's call can also be found in today's press release. Our Form 10-Q and other reports filed with the SEC along with today's press release, our updated investor presentation, and a replay of today's call can be found on our website under the investor section. Now I will turn the call over to Rockwell Medical's President and CEO, Dr. Mark Strobeck. Mark Strobeck: Thank you, Heather, and good morning, everyone. Thank you for joining us today on Rockwell Medical's second quarter 2026 earnings conference call and webcast. The second quarter was another important step forward for Rockwell Medical. We delivered strong year-over-year growth, continued to expand gross margin, generated positive operating cash flow, strengthened our customer portfolio, and advanced the operational initiatives that we believe will continue to drive long-term shareholder value. As a result, we remain on track to achieve our full-year 2026 guidance while continuing to execute against our strategy for further growth in the years ahead. When I think about where Rockwell is today compared to just a few years ago, the difference is significant. Our focus over the last several years has been …

Equipo directivo de RMTI

6 directivos

Nombre	Cargo	Remuneración	Género	Año de nacimiento	Estado
Mark Strobeck	President, Chief Executive Officer & Director	USD 1,033,700	—	1971	Active
Megan C. Timmins	Executive Vice President, Chief Legal Officer & Secretary	USD 611,400	Female	1973	Active
Jesse Neri	Senior Vice President & Chief Financial Officer	USD 462,050	Male	1978	Active
Nicholas Fanslau	Controller & Principal Accounting Officer	—	Male	1985	Active
Timothy T. Chole	Senior Vice President & Chief Commercial Officer	—	Male	1974	Active
Heather H. Hunter	Senior Vice President & Chief Operating Officer	—	Female	1979	Active

Noticias recientes de RMTI

Seeking Alpha13/8/2026Neutral

Rockwell Medical, Inc. (RMTI) Q2 2026 Earnings Call Transcript

Zacks Investment Research13/8/2026Neutral

Rockwell Medical (RMTI) Reports Q2 Loss, Lags Revenue Estimates

Rockwell Medical (RMTI) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.5 per share a year ago.

GuruFocus13/8/2026Neutral

Rockwell Medical Announces Second Quarter 2026 Results

Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodial

Business Wire13/8/2026Neutral

Rockwell Medical Announces Second Quarter 2026 Results

WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical announces Q2'26 results, delivering strong year-over-year growth, expanding gross margin and generating positive operating cash flow.

Zacks Investment Research6/8/2026Neutral

Rockwell Medical (RMTI) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Rockwell Medical (RMTI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Evolución del número de empleados de RMTI

Actual

157

Cambio

-35.66%

Mínimo

157

Máximo

300

Presentaciones recientes

Fecha del informe	Empleados	Tipo de formulario	Fecha de presentación	Archivo SEC
31 dic 2025	157	10-K	26 mar 2026	Ver
31 dic 2024	244	10-K	20 mar 2025	Ver
31 dic 2023	237	10-K	21 mar 2024	Ver
31 dic 2022	253	10-K	30 mar 2023	Ver
31 dic 2021	300	10-K	8 abr 2022	Ver

Acciones relacionadasDrug Manufacturers - Specialty & Generic

Ver todas las acciones de EE. UU. →

Sobre nosotrosPolítica de privacidadTérminos de servicioAviso legalDirectorio de accionesETFÍndicesCarteras 13FPrecios objetivoHerramientas gratuitasMapa tecnológicoÚnete a nuestro Slack

Plutux no es un asesor de inversiones. Los datos de mercado y el análisis generado por IA son solo informativos y educativos, no asesoramiento de inversión. Aviso legal

Rockwell Medical, Inc.